Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Issue 1 (5th January 2023)

• Record Type: Journal Article
• Authors: Humbert, Marc; McLaughlin, Vallerie; Gibbs, J. Simon R.; Gomberg-Maitland, Mardi; Hoeper, Marius M.; Preston, Ioana R.; Souza, Rogerio; Waxman, Aaron B.; Ghofrani, Hossein-Ardeschir; Escribano Subias, Pilar; Feldman, Jeremy; Meyer, Gisela; Montani, David; Olsson, Karen M.; Manimaran, Solaiappan; de Oliveira Pena, Janethe; Badesch, David B.
• Is Part Of: European respiratory journal. Volume 61:Issue 1(2023)
• Publication Date: 2023-01-05
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01347-2022
• Languages: English
• ISSNs: 0903-1936

Abstract

Background: In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo. This report characterises the longer-term safety and efficacy of sotatercept in the PULSAR open-label extension. We report cumulative safety, and efficacy at months 18–24, for all participants treated with sotatercept. Methods: PULSAR was a phase 2, randomised, double-blind, placebo-controlled study followed by an open-label extension, which evaluated sotatercept on top of background pulmonary arterial hypertension therapy in adults. Participants originally randomised to placebo were re-randomised 1:1 to sotatercept 0.3 or 0.7 mg·kg −1 (placebo-crossed group); those initially randomised to sotatercept continued the same sotatercept dose (continued-sotatercept group). Safety was evaluated in all participants who received ≥1 dose of sotatercept. The primary efficacy endpoint was change from baseline to months 18–24 in pulmonary vascular resistance. Secondary endpoints included 6-min walk distance and functional class. Two prespecified analyses, placebo-crossed and delayed-start, evaluated efficacy irrespective of dose. Results: Of 106 participants enrolled in the PULSAR study, 97 continued into the extension period. Serious treatment-emergent adverse events were reported in 32 (30.8%) participants; 10 (9.6%) reported treatment-emergent adverse events leading to study discontinuation. Three (2.9%) participants died, none considered related to study drug. The placebo-crossed group demonstrated significant improvement across primary and secondary endpoints and clinical efficacy was maintained in the continued-sotatercept group. Conclusion: These results support the longer-term safety and durability of clinical benefit of sotatercept for pulmonary arterial hypertension. This report characterises the longer-term safety and efficacy of sotatercept in adult participants with pulmonary arterial hypertension from the PULSAR open-label extension period https://bit.ly/3QqezKH